Many studies have shown that CSCs, such as CD133+ cells of glioblastoma and pancreatic ductal adenocarcinoma, ROSlow quiescent leukemia stem cells, and lung and breast cancer stem cells have upregulated the OXPHOS signature and rely on the OXPHOS phenotype for their high metabolic demands 42-45. The gene discussed is PROM1; the disease is pancreatic ductal adenocarcinoma.